RWJ-51204
RWJ-51204
RWJ-51204 (pronunciation: /ɑːr dʌbəljuː dʒeɪ faɪf wʌn tuː oʊ fɔːr/) is a pharmacological compound that is classified under the category of anxiolytic drugs. It is known for its potential in treating anxiety disorders and related conditions.
Etymology
The term "RWJ-51204" is a systematic name given by the pharmaceutical company Johnson & Johnson, where "RWJ" stands for Robert Wood Johnson, the founder of the company. The numbers "51204" are arbitrary and do not carry any specific meaning.
Pharmacology
RWJ-51204 is a non-benzodiazepine anxiolytic that acts as a partial agonist at GABAA receptors. It is believed to have a similar mechanism of action to other non-benzodiazepine anxiolytics, such as buspirone and gepirone, but with a different chemical structure.
Clinical Use
RWJ-51204 has been studied for its potential use in the treatment of Generalized Anxiety Disorder (GAD) and other related anxiety disorders. However, as of now, it is not approved for any medical use by any health authority.
Related Terms
- Anxiolytic: A class of medication used to treat anxiety and related disorders.
- GABAA receptors: A type of protein within the body that RWJ-51204 interacts with to produce its effects.
- Buspirone: A non-benzodiazepine anxiolytic with a similar mechanism of action to RWJ-51204.
- Gepirone: Another non-benzodiazepine anxiolytic with a similar mechanism of action to RWJ-51204.
External links
- Medical encyclopedia article on RWJ-51204
- Wikipedia's article - RWJ-51204
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski